AI-generated · cited to primary sources · not investment advice · How we research
Gland Pharma
Our verdict on Gland Pharma isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
For the 9 months ended FY26, adjusted EBITDA increased by 26%, and the Q3 FY26 consolidated EBITDA margin stood at 26%, tracking ahead of the full-year guidance range. (3 exceeded, 2 met across 5 tracked commitments)
“We're targeting around 35%, now it's 37%.”
R&D expenses for Q3 FY26 were 5.4% of revenue, and for the 9M FY26 period, they stood at 5.2% (INR 1,725 million out of INR 32,965 million base revenue), aligning with the ~5% guidance. (3 met across 3 tracked commitments)
“Yes, roughly, we always say around 5% on an annual basis, it should be around that.”
The company confirmed that three products remain in line for approval following the successful launch of six others in the complex pipeline. (5 met across 5 tracked commitments)
“I'm pleased to inform you that our partner has received approval for liraglutide in the U.S., and we are ready for the U.S. launch in this quarter.”
Cenexi achieved the targeted revenue run rate of EUR 50 million in Q3 FY26 and reported a positive EBITDA of EUR 1.4 million (INR 148 million), successfully reaching the breakeven goal. (4 met, 1 revised across 5 tracked commitments)
“As a consol, we are looking at around 13%, 12% to 13% growth. So it's a mix of both Cenexi and base business. This is excluding the GLP, whatever we get upside on that.”
The launch has shifted slightly from the September quarter to the current quarter (Q3 FY26), with the goal date set for November 2025. (3 revised, 1 met across 4 tracked commitments)
“The other big thing in the US will be Dalbavancin launch. That will be the September quarter. That's on track again in terms of the approval and launch.”
See the full cited Management analysis of Gland Pharma
How durable is the business?
The base business saw improved profitability margins, with gross margins rising to 59% from 53% in the previous year's quarter, primarily due to favorable raw material costs. (1 expanding)
“Excluding Cenexi, our base business gross margin stood at 59% in Q1 FY '26, up from 53% in the same quarter of previous year.”
The regulatory moat is maintained through consistent R&D investment (5.8% of revenue) and a steady stream of new ANDA filings and approvals. (2 stable)
“We invested 5.8% of revenue in R&D this quarter... We filed six ANDAs and received five approvals this quarter.”
The US market remains the largest revenue contributor at 49%, though it faced a slight 2% decline in revenue due to the timing of Enoxaparin supplies, which was partially offset by nine new product launches. (2 contracting, 3 expanding)
“The U.S. reported INR 7,443 million in revenues, contributing to 49% of our business.”
Cenexi is the company's European subsidiary providing contract manufacturing and development services, which saw a turnaround to positive EBITDA this quarter. — Cenexi (27.4% revenue share)
“Cenexi Updates... Revenue from operations 4,780... EBITDA % margin 1%”
Gland Pharma maintains a significant competitive advantage through its extensive pipeline of Abbreviated New Drug Applications (ANDAs), with 388 filings in the US and a high approval rate.
“contributing to a cumulative total of 388 ANDA filings in the U.S. (337 approved, 51 pending).”
See the full cited Business Model analysis of Gland Pharma
Where does growth come from?
The expansion of pen and cartridge capacity is accelerating, with the current 40 million unit line already approved and a massive 100 million unit addition reaching the Factory Acceptance Test (FAT) stage by September 2025. (5 accelerating across 5 signals, 5 leading indicators)
“GLP-1s and Insulin analogs: In FY26, the company launched Liraglutide in the US. Our Pen/cartridge capacity now stands at 140 million units per annum.”
Cenexi's turnaround is accelerating, moving from several quarters of losses to EBITDA breakeven, supported by the commercial start of the new Fontenay Line G. (3 accelerating, 2 new trend across 5 signals, 3 leading indicators)
“The next four years, we're looking at a CAGR of 15% at a consol basis.”
The Cenexi (CDMO) segment is showing strong revenue recovery, growing 20% YoY and 19% QoQ, reaching EBITDA breakeven for the first time since acquisition. (5 accelerating across 5 signals)
“The CDMO business represented 46% of total revenues supported by healthy growth of 28%, driven by our continued strategic focus on investments.”
US revenue growth is accelerating, with Q4 FY26 showing a 24% YoY increase compared to the full-year FY26 growth of 13%, supported by a robust pipeline of 388 cumulative ANDA filings. (2 accelerating, 3 steady across 5 signals, 1 leading indicator)
“Eight ANDAs were filed, and 11 were approved in Q4 FY26... contributing to a cumulative total of 388 ANDA filings in the U.S. (337 approved, 51 pending).”
Cenexi's Fontenay facility is adding a high-capacity line to become the largest ampoule site in Europe, with a clear timeline for 2027. (2 new trend, 1 steady across 3 signals, 1 leading indicator)
“Europe Market Group Revenue Contribution FY26: 14,035 Mn (34% YoY). Cenexi: Ramp-up of an inactivated vaccine and a sterile ophthalmic gel resulted in increased revenue.”
See the full cited Future Growth analysis of Gland Pharma
What could break the thesis?
The risk is stable but showing slight improvement as US revenue contribution dropped to 49% this quarter from over 50% previously, while other regulated markets grew 34%. (1 stable, 1 easing, 1 high-severity)
“Starting with the United States, which continues to remain our largest market... for the full year, revenue stood at INR33,181 million with a growth of 11%.”
The risk is easing as the company confirmed that Liraglutide has now been launched in Saudi Arabia, indicating a resumption of business activity. (5 easing, 1 high-severity)
“US Contribution to the Group FY26 53%”
The risk is easing as the number of pending ANDAs has decreased from 51 to 47, with 9 approvals received in the current quarter. (4 easing, 1 stable, 1 high-severity)
“contributing to a cumulative total of 388 ANDA filings in the U.S. (337 approved, 51 pending).”
The risk is intensifying as R&D expenses as a percentage of revenue increased to 5.8% in Q2 FY26 from 4.6% in Q2 FY25. (2 intensifying, 1 easing, 2 stable)
“Total R&D expenses were ₹506 million in Q4 FY26, representing 4% of base business revenue. The R&D expenditure was mainly focused on complex product development”
The risk is easing as Cenexi has achieved EBITDA breakeven after several quarters of losses, with gross margins improving from 78% to 80%. (2 easing, 1 stable)
“And most of the volumes, as you know, comes from U.S. where the patent is post 2030. So the ramp-up will happen mostly during that time... it's very difficult to assume numbers without actually having to know when the approvals will come in which market.”
See the full cited Risk analysis of Gland Pharma
Read the full thesis on Gland Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.